Clinical and Anti-Oxidant Effect of Adding CoQ10 to Biological Therapy in Treating Moderate to Severe Psoriasis

Aims: Psoriasis is a complex, chronic, immune-mediated, and hereditary skin disease. The present study attempted to determine whether adding CoQ10 to biological therapy can help relieve inflammation in Iraqi patients suffering from moderate to severe psoriasis. Materials Methods: A prospective, double-blind clinical trial took place in the Department of Dermatology at Merjan Teaching Hospital in Babylon, Iraq, over three months from August to November 2021. 30 individuals from 17 to 72 years old with persistent plaque psoriasis who met the criteria for biological therapy were selected by the available sampling method. Participants were allocated into two groups (each 15 members); Group A was treated with Adalimumab + placebo (corn starch), and Group B was treated with Adalimumab + 100mg CoQ10 adjuvant. The Psoriasis Area and Severity Index (PASI) score was utilized. The sera were utilized to calculate the human superoxide dismutase and malondialdehyde via the ELISA technique. Findings: When compared to the patients before treatment, the two groups showed a substantial decline (p 0.05) after treatment; However, group B, which added CoQ10 to biological treatment, showed a highly significant decrease (p 0.05) in mean SOD level and MDA after treatment. Furthermore, following twelve weeks of treatment, group B’s use of combined adjuvant therapy showed even greater recovery, as indicated by a 79% PIC PASI score improvement instead of a 60% PIC score. Conclusion: Daily administration of 100mg CoQ10 supplements to psoriatic subjects for 12 weeks has beneficial effects on reducing oxidative stress.